Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma

Reportstack has announced a new market research publication on Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma. In the coming years, a few innovations from Japanese global companies will significantly change some key therapy paradigms and may bring back innovation driven reputation of Japan Pharma. Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi will bring good times back to respective companies in 2013 and these catalysts carry potential to change the global market dynamics in anticoagulant, diabetes and HIV space. Changing political scenario in Japan will accelerate the pace of reforms in Japan; recently, the Liberal Democratic Party (LDP) of Japan came back into power replacing the short tenure of the Democratic Party of Japan (DPJ). LDP was the pioneer initiator of major healthcare reforms with a focus on curbing healthcare costs by means of enhancing generic drugs penetration. Our report discusses in details about the implications of these changes on Innovator and generic domestic Japanese pharma companies.
We think that the massive ~$45b poured in acquiring innovation by Japanese companies will never justify its value and we find that the key catalysts from Japan are in-housed candidates. Global companies on other hand going to see a favorable scenario in coming years - expected launches in 2013-2014 from global companies will increase competition to domestic players mainly in respiratory, oncology and rheumatoid arthritis therapy areas, and will increase overall market size of Diabetes and Osteoporosis markets.
Going forward, for 2013 –Generic companies will continue to witness a growth story, we think that the recent incentives to promote generic uptake have played out well and at current levels we do not see meaningful growth until early 2014 when new set of incentives will start playing off. However, in the related space – drug chain stores and biogenerics are two new arenas which we see as the next growth driver– we have analyzed these two novel spaces as well in this piece.

To view the table of contents and know more details please visit Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma report.